News
-
-
PRESS RELEASE
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%
Valbiotis announces the launch of a €10.2M capital increase with 76.6% secured commitments to fuel commercial expansion. The offering includes subscription price at €0.86/share, a discount, and expansion plans in Asia and the Middle East -
-
-
PRESS RELEASE
VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East
Valbiotis signs exclusive distribution agreement with Al Danah Medical Company in Qatar, expanding presence in the Middle East. Launch of 4 products in 2027 -
PRESS RELEASE
VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East
Valbiotis signs exclusive distribution agreement in Qatar with Al Danah Medical Company, marking a milestone in brand's Middle East expansion. Agreement includes launch of 4 products. First revenues expected in 2027 -
-
-
-
PRESS RELEASE
VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice
EU Member States vote in favor of banning monacolins from red yeast rice, impacting Valbiotis. The new regulation validates Valbiotis' scientific approach to cardiometabolic prevention
